Shenzhen Hepalink Pharmaceutical Group has patented a softgel capsule containing berberine, EPA, DHA, and other components for treating metabolic diseases, heart diseases, liver diseases, inflammation, and more. The pharmaceutical composition aims to improve liver function and prevent various disorders. GlobalData’s report on Shenzhen Hepalink Pharmaceutical Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Shenzhen Hepalink Pharmaceutical Group, Transgenic murine models was a key innovation area identified from patents. Shenzhen Hepalink Pharmaceutical Group's grant share as of February 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.
Pharmaceutical composition for treating metabolic diseases and liver disorders
A recently granted patent (Publication Number: US11883539B2) discloses a softgel capsule containing a unit dose of a pharmaceutical composition. The composition includes berberine (BBR) in the form of a chloride, sulfate, or citrate salt, along with eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) in their ethyl ester forms. Additionally, the pharmaceutical composition contains a pharmaceutically acceptable excipient, carrier, or diluent.
The patent further specifies that the weight ratio of BBR to EPA/DHA in the softgel capsule ranges from about 1:1 to about 1:8. The unit dosage form of the capsule includes BBR in the range of about 100 mg to 300 mg and EPA/DHA in the range of about 100 mg to 800 mg. This innovative softgel capsule formulation aims to provide a convenient and effective delivery system for the combination of BBR, EPA, and DHA, offering potential benefits in various therapeutic applications.
To know more about GlobalData’s detailed insights on Shenzhen Hepalink Pharmaceutical Group, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
